Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood draws could spot dementia years early

NCT ID NCT04516499

Knowledge-focused Sponsor: The Bluefield Project to Cure Frontotemporal Dementia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks a protein called neurofilament light chain in the blood of 342 people who carry genetic mutations linked to frontotemporal dementia (FTD). Participants provide blood samples every three months for three years, often from home. The goal is to see if this biomarker can reliably signal disease onset or progression, which could help design future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors detect frontotemporal dementia earlier and monitor its progression using simple blood tests.
What could go wrong
This is an observational study, not a treatment trial. It may not directly lead to new therapies, and results may not apply to all forms of dementia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

342 people

The number who actually took part.

Started

Sep 2020

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study is an ancillary study to ALLFTD. Thus, all NSP participants will be recruited directly from the longitudinal arm of ALLFTD. Roughly equivalent numbers of participants will be enrolled from each of the following groups: * Members of families with known mutations in C9orf72 * Members of families with known mutations in GRN * Members of families with known mutations in MAPT Although participant must be from a family with a known mutation, the participant themselves need not know their personal mutation status.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female 2. Ages 18-85 3. Provision of signed and dated informed consent form 4. Stated willingness to comply with all study procedures and availability for the duration of the study 5. Is enrolled in the longitudinal arm of ALLFTD 6. Is a member of a family with a known mutation in C9orf72, GRN or MAPT Exclusion Criteria: 1. Any permanent contra-indication to repeated blood draws, such as poor venous access. 2. Any conditions or circumstances which, in the opinion of the investigator, would not allow participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Frontotemporal dementia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

frontotemporal dementia frontotemporal dementia with motor neuron disease Frontotemporal Lobar Degeneration semantic dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Frontotemporal dementia Frontotemporal lobar degeneration FTD FTD-GRN FTLD

Contacts and locations

Locations

  • Columbia University

    New York, New York, 10032, United States

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland, 21287, United States

  • Massachusetts General Hospital

    Charlestown, Massachusetts, 02129, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Mayo Clinic Florida

    Jacksonville, Florida, 32224, United States

  • University of California, San Francisco

    San Francisco, California, 94158, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • Washington University in St. Louis

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.